Company intelligence / Profile preview
HCT Regenerative
Tamsui, New Taipei City, Taiwanhctregenerative.com ↗
- Ownership
- Private
- Employees
- ~35
- Development stage
- Other
01
Overview
HCT Regenerative is a leader in tissue engineering and cell therapy in Taiwan, operating the region's only AATB-accredited tissue bank. The company has successfully commercialized tissue-based products like AmnioGen and is currently advancing autologous cell therapies HCT-1 and HCT-2 through clinical trials for hair follicle and cartilage regeneration, showing promising safety and efficacy profiles in early-stage studies.
- Therapeutic areas
- OphthalmologyRheumatologyDermatology
- Modalities
- Cell therapyStem cell therapyBiologicInduced pluripotent stem cell derived therapyTissue engineering
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
National Taiwan UniversityNational Health Research Institutes (NHRI)
Beyond the preview
Go deeper on HCT Regenerative.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCT Regenerative.